NCT06031181

Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)

Recruiting now Phase 3 Last updated 13 December 2023

What this trial tests

Phase 3 trial testing Sublobar Resection in Lung Adenocarcinoma in 390 participants. Currently enrolling.

Timeline

31 March 2023

Primary endpoint
1 January 2026

31 December 2030

Quick facts

Lead sponsor	Fudan University
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	390
Start date	31 March 2023
Primary completion	1 January 2026
Estimated completion	31 December 2030
Sites	1 location across China

Drugs / interventions tested

• Sublobar Resection

Conditions studied

• Lung Adenocarcinoma — all drugs for Lung Adenocarcinoma →
• Frozen Section — all drugs for Frozen Section →
• Sublobar Resection — all drugs for Sublobar Resection →

Sponsor

Fudan University

Who can join

Adults 18 to 80, any sex, with Lung Adenocarcinoma or Frozen Section. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1019. The goal of this clinical trial is to confirm the therapeutic effect of sublobar resection for AIS/MIA diagnosed by intraoperative frozen section.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Sublobar resection for adenocarcinoma <i>in situ</i> and minimally invasive adenocarcinoma diagnosed by intraoperative frozen section (ECTOP-1019): a study protocol of prospective, single-arm, multicenter, phase III study.
   Zheng S, Deng C, Li Y, Zhang Y, et al · · 2024 · cited 1× · PMID 39444881 · DOI 10.21037/jtd-24-623
2. Function-preserving radical surgery for early-stage non-small cell lung cancer: A review of limited resection approaches.
   Ohtaki Y, Aokage K, Miyoshi T, Tane K, et al · · 2026 · PMID 41642077 · DOI 10.1093/jjco/hyag013